Tarsus Pharmaceuticals (TARS) closed at $74.85 on October 30, 2026, up 0.9% from the previous close, on volume of 420,218 shares (30-day average 903,804).
Data as of October 30, 2026.
30-Oct-2026
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Globe Newswire (Thu, 29-Oct 4:30 PM ET)
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
Globe Newswire (Wed, 28-Oct 8:30 AM ET)
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Globe Newswire (Wed, 14-Oct 4:05 PM ET)
Globe Newswire (Tue, 29-Sep 8:30 AM ET)
Globe Newswire (Fri, 4-Sep 8:38 AM ET)
Globe Newswire (Thu, 3-Sep 11:10 AM ET)
Tarsus to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 4:30 PM ET)
Globe Newswire (Mon, 24-Aug 8:30 AM ET)
Tarsus Delivers Strong Q2 Growth: XDEMVY Drives Revenue Surge and Retina Pipeline Expands
Market Chameleon (Thu, 6-Aug 3:49 AM ET)
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Globe Newswire (Thu, 6-Aug 7:03 AM ET)
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals trades on the NASDAQ stock market under the symbol TARS.
As of October 30, 2026, TARS stock price climbed to $74.85 with 420,218 million shares trading.
TARS has a beta of 0.16, meaning it tends to be less sensitive to market movements. TARS has a correlation of 0.00 to the broad based SPY ETF.
TARS has a market cap of $3.50 billion. This is considered a Mid Cap stock.
Last quarter Tarsus Pharmaceuticals reported $174 million in Revenue and -$.43 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.18.
In the last 3 years, TARS traded as high as $91.53 and as low as $13.90.
The top ETF exchange traded funds that TARS belongs to (by Net Assets): VTI, FBT, IWM, VXF, IWO.
TARS has underperformed the market in the last year with a return of +8.5%, while SPY returned +12.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TARS shares. However, TARS has outperformed the market in the last 3 month and 2 week periods, returning +25.7% and +10.0%, while SPY returned +2.1% and -1.0%, respectively. This indicates TARS has been having a stronger performance recently.
TARS support price is $72.05 and resistance is $76.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TARS shares will trade within this expected range on the day.
